Get notified when TELO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTelomir announces peer-reviewed preclinical study showing drug reduced liver injury in disease model
Filed May 20, 2026 · Period ending May 20, 2026 · ~1 min read
Key Changes
-
medium
Telomir-1 reduced oxidative stress, liver copper buildup, and injury markers in a zebrafish model of Wilson's disease, a genetic disorder causing toxic copper accumulation in organs.
Press Release, May 20, 2026 view on EDGAR → -
medium
Study published in peer-reviewed journal Advances in Redox Research, providing independent scientific validation of the company's lead drug candidate in preclinical testing.
Press Release, May 20, 2026 view on EDGAR → -
medium
Drug improved survival outcomes and locomotor performance in the animal model, suggesting potential therapeutic benefit beyond just biochemical markers.
Press Release, May 20, 2026 view on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (THRM 10-Q) is open in full — no account needed.
Partner
Trade TELO commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify